POLYTECH Health & Aesthetics Wins Temporary Stay Against Preliminary Injunction in Munich Court Case

POLYTECH Health & Aesthetics GmbH has announced that the Munich Higher Regional Court has granted a temporary stay on the enforcement of a preliminary injunction issued by the Munich Regional Court I. This key court ruling, dated August 20, 2026, allows POLYTECH to proceed with an appeal regarding a judgment made on April 2, 2026, while ensuring the company’s operations can continue without interruption.

Overview of the Legal Proceedings

The order from the Munich Higher Regional Court came as a significant relief for POLYTECH. The court ruled that the initial reasoning behind the enforcement of the preliminary injunction was insufficient. The appellate ruling indicates that enforcement should be paused while the arguments surrounding the merits of the case continue to be evaluated in the higher court.

The Munich Higher Regional Court emphasized that the issues raised in the appeal deserve careful consideration and that the underlying assessment from the first-instance ruling concerning POLYTECH's manufacturing processes lacked clarity. The specifics of the case revolve around patent claims associated with these processes, which have become a contentious point during the ongoing litigation against competitors.

Implications for POLYTECH and Operations

POLYTECH's decision to appeal comes after it provided the necessary security as required by the court, which means the company can avoid enforcement of the preliminary injunction during the appeal phase. However, it’s critical to note that this stay does not equate to a final decision on the patent dispute or even all the issues related to the merits of their claims.

With this court decision, POLYTECH now seeks to resume its affected business activities in compliance with the court's order and all relevant legal frameworks. The management is optimistic that the additional arguments presented about the alleged patent issues will have substantial weight in the appellate court’s evaluations moving forward.

Continued Legal Engagement

Professor Dr. med. Karsten Hemmrich, CEO of POLYTECH Health & Aesthetics, expressed confidence in their legal position, stating, "The Higher Regional Court's order is an important correction to the immediate effects of the first-instance judgment. It recognizes that the reasoning supporting enforcement was insufficient and restores essential flexibility while the appeal is heard."

This statement reflects POLYTECH's commitment to fully articulate its defense throughout the legal process, ensuring all stakeholders including employees, customers, and investors are duly informed of significant developments as they occur.

Moving Forward

As the wait continues for a final resolution on the dispute over the patent claims related to POLYTECH's manufacturing processes, the market eagerly awaits the next steps from both the company and the court. As the situation develops, it is essential for industry professionals to keep track of how these judicial trends will impact surgical practices and patient outcomes associated with the relevant products.

While the enforcement of the preliminary injunction is temporarily stayed, it remains clear that the legal battles regarding intellectual property in the medical aesthetics landscape are beyond a simple fix. This ongoing case serves as a pivotal example of the complexities manufacturers face as they navigate patent law in a rapidly evolving industry.

With a presence in over 90 countries and deep roots in manufacturing for over four decades, POLYTECH aims to not only clarify its operational stance regarding litigation but also maintain the trust that surgeons and patients have continually placed in its diverse product portfolio. As updates unfold, the company is poised to provide further information to its stakeholders and remains focused on its mission of enhancing the field of aesthetic and reconstructive surgery.

In conclusion, POLYTECH Health & Aesthetics is strategically positioned to address any effects from this legal ruling while continuing to foster innovation and patient safety in its key markets.